COMP <GO>
MRNA vs JNJ // REVENUE GROWTH (YOY)
Moderna Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: MRNA 2
— JNJ 10
▲ REVENUE GROWTH (YOY) LEADER: JNJ
LAST: $221.72 (-0.47%) • MKT CAP: $88.93B
revenue-growth
-39.90%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRNA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRNA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.30% | 67.90% | -12.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -34.10% | 25.50% | -59.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.32% | 2.97% | -5.29 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -39.90% | 6.00% | -45.90 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 15.07 | 5.59 | +9.48 | MRNA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.3 | 60.4 | -3.02 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | MRNA | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 23.0x | +9.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $88.93B | $662.49B | -$573.56B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRNA REV | JNJ REV | MRNA GROSS % | JNJ GROSS % | MRNA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.94B | $94.19B | 55.3% | 67.9% | -$2.06B | $19.70B |
| FY 2024 | $3.24B | $88.82B | 54.8% | 69.1% | -$4.05B | $19.84B |
| FY 2023 | $6.85B | $85.16B | 44.0% | 44.0% | -$3.43B | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRNA // BETA 1.10
JNJ // BETA 1.08